Madrigal Pharmaceuticals, Inc. (MDGL) Stock
Key stats
- Market cap
- $10.06B
- Price / Earnings ratio
- -64.6x
- EPS (TTM)
- -$5.87
- Volume
- Loading
- 52-week high
- $615.00
- 52-week low
- $353.54
Source: third-party data provider, as of November 13, 2026
Recent news

3 Under-the-Radar Stocks to Buy and Hold
3 Under-the-Radar Stocks to Buy and Hold
MDGL

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
MDGL

3 Biotech Stocks to Watch for Respectable Growth Beyond AI
3 Biotech Stocks to Watch for Respectable Growth Beyond AI
MDGL

3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
MDGL
Technical indicators
- RSI 14
- 44.43
- MACD 12/26/9
- -16.78
- EMA 9 of MACD
- -19.93
- MACD histogram
- 3.15
- SMA 50
- $480.46
- Price below SMA 50
- EMA 50
- $465.65
- Price below EMA 50
- SMA 200
- $496.69
- Price below SMA 200
- EMA 200
- $499.12
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

3 Under-the-Radar Stocks to Buy and Hold
3 Under-the-Radar Stocks to Buy and Hold
MDGL

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
MDGL

3 Biotech Stocks to Watch for Respectable Growth Beyond AI
3 Biotech Stocks to Watch for Respectable Growth Beyond AI
MDGL

3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
MDGL

Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now
MDGL

2 Under-the-Radar Stocks to Buy and Hold
2 Under-the-Radar Stocks to Buy and Hold
MDGL

What to Expect From These Drug/Biotech Players This Earnings Season?
What to Expect From These Drug/Biotech Players This Earnings Season?
MDGL

STVN or MDGL: Which Is the Better Value Stock Right Now?
STVN or MDGL: Which Is the Better Value Stock Right Now?
MDGL

UTHR or MDGL: Which Is the Better Value Stock Right Now?
UTHR or MDGL: Which Is the Better Value Stock Right Now?
MDGL

2 Stocks Up Over 600% in the Past 3 Years With More Room to Run
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run
MDGL
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 44.43
- MACD 12/26/9
- -16.78
- EMA 9 of MACD
- -19.93
- MACD histogram
- 3.15
- SMA 50
- $480.46
- Price below SMA 50
- EMA 50
- $465.65
- Price below EMA 50
- SMA 200
- $496.69
- Price below SMA 200
- EMA 200
- $499.12
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $633.00
- Average
- $710.00
- High
- $760.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -8.5 | +5.6 | ||||||||||
| 2022 | -36.1 | +48.4 | +0.1 | -30.1 | -7.1 | +8.4 | -14.6 | +19.1 | -11.8 | +9.3 | -5.2 | +297.0 |
| 2023 | +1.0 | -6.2 | -13.2 | +25.4 | -10.0 | -14.1 | -9.1 | -11.0 | -21.1 | -8.4 | +48.9 | +8.6 |
| 2024 | -4.5 | +6.3 | +6.1 | -20.2 | +12.1 | +14.1 | +2.3 | |||||
| 2026 | +9.3 |



